|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.65 HKD | -0.35% |
|
0.00% | -16.05% |
An unknown buyer entered into an agreement to acquire 35% stake in Shanghai Celgen Bio-Pharmaceutical Co., Ltd. from Simcere Pharmaceutical Group. (NYSE:SCR) for approximately CNY 300 million on January 15, 2013. The transaction is subject to certain closing conditions.
Carly Westerman, Yue Yu and Joseph Lo Chi-Lun of Brunswick Group LLC acted as PR advisors to Simcere Pharmaceutical.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.05% | 1.84B | |
| +26.58% | 45.33B | |
| +38.49% | 25.36B | |
| +27.57% | 16.7B | |
| +20.89% | 14.59B | |
| +72.03% | 14.26B | |
| -0.05% | 6.79B | |
| -10.35% | 6.67B | |
| -8.87% | 5.73B | |
| +13.07% | 5.62B |
SIMCERE PHARMACEUTICAL GROUP LIMITED 
